Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Kim, Sang Deuk; Park, Jong Kwan

doi:10.5534/kja.2011.29.2.91

Cited by 4 publications

(8 citation statements)

References 63 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Porst and colleagues in 2009 reported similarly on the efficacy of tadalafil, with changes in IPSS, Qmax and PVR which were small and statistically insignificant [25, 26]. The IPSS findings from the present study were consistent with those from other studies of tadalafil 5 mg and tamsulosin 0.4 mg in Asian and non-Asian men with LUTS secondary to BPH [27–32]. Oelke M et al, in a randomized control trial evaluating tadalafiland tamsulosin for LUTS secondary to BPH, suggested that monotherapy with tadalafilor tamsulosin resulted in a significant and numerically similar improvement in IPSS versus placebo, which is in contrast to our study [2].…”

Section: Discussionsupporting

confidence: 88%

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized

Pogula

Kadiyala

Gouru

et al. 2019

Cent European J Urol

View full text Add to dashboard Cite

Introduction To compare the efiicacy of tadalafil 5 mg with tamsulosin 0.4 mg in the treatment of Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Material and methods A randomized prospective study on patients diagnosed with LUTS secondary to BPH with 50 patients in each group. Duration of the study is 12 weeks. Drug was given 30 min after dinner. Patients were assessed at baseline 1, 4 and 12 weeks with efficacy measures being Maximum flow rate (Qmax), Postvoid residual urine (PVR), International Prostate Symptom Score (IPSS), International Prostate Symptom Score Quality of life (IPSS QoL) and Sexual Health Inventory for Men (SHIM) scoring. Statistical analysis was done using paired sample t test and independent sample t test. Results In tadalafil group, 12 (24%) patients were having mild LUTS and 38 (76%) were having moderate LUTS. In tamsulosin group, 9 (18%) patients were having mild LUTS and 41 (82%) patients were having moderate LUTS. Seventeen patients in tadalafil group had associated ED (erectile dysfunction) and 13 patients had associated ED in tamsulosin group. Conclusions When both groups were compared, tamsulosin showed better efficacy than tadalafil in treating LUTS secondary to BPH.

show abstract

Section: Discussionsupporting

confidence: 88%

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized

Pogula

Kadiyala

Gouru

et al. 2019

Cent European J Urol

View full text Add to dashboard Cite

show abstract

“…Many studies have demonstrated the effects of the nitric oxide pathway on symptoms related to lower urinary tract disorders [ 10 , 11 , 13 , 14 , 25 – 27 ]. In the study performed by Kim et al [ 10 ], four different reasons were proposed to explain how the nitric oxide pathway was related to lower urinary tract symptoms/BPH. In BPH, the reduction in nitric oxide bioavailability was related to BPH and LUTS.…”

Section: Discussionmentioning

confidence: 99%

“…In our study, eNOS and nNOS played an important role in the nitric oxide pathway, and previous studies have shown that the berry mixture affects the stimulation or enhancement of the nitric oxide pathway [ 6 , 7 , 9 , 16 ]. In addition, there is evidence that the nitric oxide pathway and the related drug have an effect via controlling the ED and LUTS [ 10 , 11 , 13 , 14 , 25 , 28 ]. Kedia et al [ 25 ] observed that the enhancement of nitric oxide and the nitric oxide pathway signaling enzymes such as eNOS, nNOS, cGMP, cGK played an important role in smooth muscle contraction in human prostate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of a combination of herbal extracts (modified Ojayeonjonghwan (Wuzi Yanzong wan)) on partial urethral obstruction-induced detrusor overactivity in rats: impact on the nitric oxide pathway and oxidative stress

Bae

Lee

Jeong

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

sBackgroundWe investigated the effects of a berry mixture formula (modified Ojayeonjonghwan (Wuzi Yanzong Wan, MO formula) on detrusor overactivity (DO).MethodsThe MO formula consisted of 5 seeds obtained from 5 types of berry plants. Twenty-four Sprague-Dawley rats were randomly assigned to four groups: sham-operated (control), partial urethral obstruction-induced DO (DO group), 0.03 mg/kg solifenacin-treated DO (solifenacin group) and 200 mg/kg MO formula -treated DO (berry mixture). The control and overactive groups were administered distilled water for 4 weeks, and the solifenacin and MO formula groups were treated with the respective medication for 4 weeks. After treatment, cystometrography was performed. At the endo of cystometrography, their bladder tissues were used for identifying the muscarinic receptors, endothelial nitric oxide synthase(eNOS), RhoA, Rock-I & II, 8-hydroxy-2′ –deoxyguanosine(8-OHdG), superoxide dismutase(SOD), interleukin-6 &-8(IL-6, IL-8), and tumor necrosis factor-alpha(TNF-a). The tissues were stained and the muscle-to-collagen ratio was identified.ResultsThe presence of the muscarinic receptors were not significantly different between the solifenacin and MO formula groups. However, significant differences were found between the solifenacin and MO formula groups in terms of eNOS, RhoA, Rock-I and -II levels. The muscle-to-collagen ratio was statistically lower in the DO and solifenacin groups; however, no significant difference was observed between the control and MO formula groups. Under oxidative stress, SOD showed a similar result as 8-OHgG. The MO formula group exhibited anti-inflammatory effects, showing that no significant difference was found between the control and MO formula groups regarding values of IL-6, IL-8, and TNF-a. However, the DO and solifenacin groups showed increased IL-6, IL-8, and TNF-a levels. Cystometrography showed that the OAB and solifenacin groups having a significantly lower value than the control and MO formula groups. The mean contraction interval was shorter in the DO, MO formula, and solifenacin groups and the highest in the control group.ConclusionsThe MO formula exhibited a similar pharmacologic effect to that of solifenacin, with anti-inflammatory and antioxidant effects. Enhancement of the MO formula by the nitric oxide pathway affected DO including BPH-related DO. The MO formula may be one of the alternative choices of anticholinergics, a treatment for DO.

show abstract

“…LUTS was an independent risk factor for ED [21] . Several mechanisms have been proposed to explain the relationship between LUTS and ED, including pelvic reduction in nitric oxide synthase (NOS)/nitric oxide (NO) [22,23] and autonomic nervous system over activity [22][23][24][25][26] . Abnormal up regulation of the Rho A/Rho kinase (ROCK) pathway, which mediates smooth muscle contraction, might also contribute to the lack of smooth muscle relaxation in the prostate, urethra, bladder neck, and penis [23][24][25] .…”

Section: Discussionmentioning

confidence: 99%

Combination of alfa blocker with low dose tadalafil in benign prostatic hyperplasia with erecticle dysfunction management

Reddy

Shaik²

2017

IJMSCI

View full text Add to dashboard Cite

To study the combination therapy with daily low dose tadalafil (5mg) and alpha blockers for the treatment of BPH-LUTS and Erecticle dysfunction (ED). Materials and Methods: The medical records of 168 patients who had medical management for symptomatic BPH/LUTS with or without ED from January 2010 to December 2013 were reviewed retrospectively. All patients were divided into 2 groups. Group-1(n: 74) included patients received a single daily dose of tamsulosin 0.4mg or alfuzosin 10mg. Group-2 (n:75) patients with LUTS and BPH who were previously managed with alpha blockers (tamsulosin 0.4mg or alfuzosin 10mg) were included in our study by addition of 5mg phosphodiesterase type 5 inhibitor (tadalafil), which has been reported to be useful in the management of BPH/LUTS and ED. We analysed the International Prostate Symptom Score (IPSS), IIEF Score, BPH Impact Index (BII) and Quality of Life (QoL). Results: Before the inclusion of tadalafil patients exclusively on alpha blockers had a mean IPSS score of 21.51 ± 2.89). IPSS improved to a mean of 11.34 ± 1.56 (p<0.001) after the addition of a single daily dose of 5mg tadalafil. A previous mean BPH Impact Index of 8.52 ± 1.22(p<0.001) improved to 4.38± 0.89 (p<0.001). Quality of Life index was graded with a mean of 3.76 ± 1.10 before addition of tadalafil and improved to a mean of 2.22 ± 0.76 (p<0.001). IIEF-5 scores changed from 15.54 ± 3.68 to 7.89 ± 3.84 (p<0.001), after 12 weeks of treatment. Conclusion: We recommend tadalafil 5mg once daily dose for BPH/LUTS patients with higher IPSS score, diabetes, smaller prostate and inoperable patients.

show abstract

Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Cited by 4 publications

References 63 publications

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized

Effects of a combination of herbal extracts (modified Ojayeonjonghwan (Wuzi Yanzong wan)) on partial urethral obstruction-induced detrusor overactivity in rats: impact on the nitric oxide pathway and oxidative stress

Combination of alfa blocker with low dose tadalafil in benign prostatic hyperplasia with erecticle dysfunction management

Contact Info

Product

Resources

About